Stefanie Cavalcanti, MD

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.

JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe